How To Limit The Use Of Serum In Viral Processes: A Gibco Perspective

Vaccine manufacturing targeting animal and human prophylaxis has relied heavily on the use of fetal bovine sera (FBS) to reach adequate titers in mammalian cell culture processes. Safety concerns, lack of process robustness, costs of qualification and storage are some of the main challenges faced while using serum. Considering these drawbacks, serum has remained one of the principal raw materials in vaccine manufacturing but with limited supply worldwide and increased demands, notably from the cell therapy industry, serum’s poor economic predictability might become a major issue on cost of good models in the future. In this poster we identify four approaches to limit the use of serum in viral processes.